(Q51999095)

19 April 2018

title

Temporary amelioration of symptoms with intravenous cyclophosphamide in amyotrophic lateral sclerosis. (English)

1 reference

19 April 2018

amyotrophic lateral sclerosis

main subject

0 references

author name string

Gourie-Devi M

series ordinal

1

1 reference

19 April 2018

Nalini A

series ordinal

2

1 reference

19 April 2018

Subbakrishna DK

series ordinal

3

1 reference

19 April 2018

publication date

1 September 1997

1 reference

19 April 2018

Journal of the Neurological Sciences

published in

1 reference

19 April 2018

volume

150

1 reference

19 April 2018

issue

2

1 reference

19 April 2018

page(s)

167-172

1 reference

19 April 2018

Association of polyclonal anti-GM1 IgM and anti-neurofilament antibodies with CSF oligoclonal bands in a young with amyotrophic lateral sclerosis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

Amyotrophic lateral sclerosis. Associated clinical disorders and immunological evaluations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases a

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

Failure of immunosuppression with a ten- to 14-day course of high-dose intravenous cyclophosphamide to alter the progression of amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

Antineural antibodies in the serum of patients with amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

A double-blind, placebo-controlled trial of TRH in amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

Amyotrophic lateral sclerosis: an unconventional autoimmune disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

Motor neuron destruction in guinea pigs immunized with bovine spinal cord ventral horn homogenate: experimental autoimmune gray matter disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

Amyotrophic lateral sclerosis. Recent advances in pathogenesis and therapeutic trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

The administration of guanidine in amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

Plasmapheresis in amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

The prognosis of motor neuron disease in Nigerian africans. A prospective study of 92 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

Differential effects of prednisone and cyclophosphamide on autoantibodies in human neuromuscular disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

Pilot trial of branched-chain aminoacids in amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

Survival prediction in sporadic amyotrophic lateral sclerosis. Age and clinical form at onset are independent risk factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

Amyotrophic lateral sclerosis: theories and therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

Serum antibodies to L-type calcium channels in patients with amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

Treatment of ALS with high dose pulse cyclophosphamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

Cyclophosphamide alters the clinical and pathological expression of experimental autoimmune gray matter disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

Amyotrophic lateral sclerosis: Part 1. Clinical features, pathology, and ethical issues in management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

Amyotrophic lateral sclerosis: Part 2. Etiopathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2900083-X

10.1016/S0022-510X(97)00083-X

7 January 2021

Identifiers

DOI

1 reference

19 April 2018

1 reference

19 April 2018